Cargando…
The Rationale of Complement Blockade of the MCP(ggaac) Haplotype following Atypical Hemolytic Uremic Syndrome of Three Southeastern European Countries with a Literature Review
We present eight cases of the homozygous MCPggaac haplotype, which is considered to increase the likelihood and severity of atypical hemolytic uremic syndrome (aHUS), especially in combination with additional risk aHUS mutations. Complement blockade (CBT) was applied at a median age of 92 months (IQ...
Autores principales: | Turudic, Daniel, Pokrajac, Danka, Tasic, Velibor, Kasumovic, Dino, Prohaszka, Zoltan, Milosevic, Danko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487996/ https://www.ncbi.nlm.nih.gov/pubmed/37685848 http://dx.doi.org/10.3390/ijms241713041 |
Ejemplares similares
-
A Limited Course of Eculizumab in a Child with the Atypical Hemolytic Uremic Syndrome and Pre-B Acute Lymphoblastic Leukemia on Maintenance Therapy: Case Report and Literature Review
por: Turudic, Daniel, et al.
Publicado: (2022) -
First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis
por: Szarvas, Nóra, et al.
Publicado: (2014) -
A case report of a child with sepsis induced multiorgan failure and massive complement consumption treated with a short course of Eculizumab: A case of crosstalk between coagulation and complement?
por: Galic, Slobodan, et al.
Publicado: (2019) -
Case report: Autoimmune hemolytic anemia caused by warm and cold autoantibodies with complement activation—etiological and therapeutic issues
por: Turudic, Daniel, et al.
Publicado: (2023) -
Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome
por: Trojnár, Eszter, et al.
Publicado: (2017)